​

Exelixis (EXEL) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

EXEL Stock Forecast

Exelixis (EXEL) stock forecast, based on 32 Wall Street analysts, predicts a 12-month average price target of $43.92, with a high of $56.00 and a low of $30.00. This represents a 2.19% increase from the last price of $42.98.

$20 $28 $36 $44 $52 $60 High: $56 Avg: $43.92 Low: $30 Last Closed Price: $42.98

EXEL Stock Rating

Exelixis stock's rating consensus is Buy, based on 32 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 17 Buy (53.12%), 15 Hold (46.88%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 32 0 15 17 Strong Sell Sell Hold Buy Strong Buy

EXEL Price Target Upside V Benchmarks

TypeNameUpside
StockExelixis2.19%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts71021
Avg Price Target$41.57$42.80$43.62
Last Closing Price$42.98$42.98$42.98
Upside/Downside-3.28%-0.42%1.49%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Nov, 25398--20
Oct, 25389--20
Sep, 25389--20
Aug, 25389--20
Jul, 25488--20
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 05, 2025Robert BurnsH.C. Wainwright$49.00$40.5220.93%14.01%
Nov 05, 2025Stephen WilleyStifel Nicolaus$43.00$38.7510.97%0.05%
Nov 05, 2025Etzer DaroutBarclays$41.00$37.908.18%-4.61%
Nov 05, 2025Silvan TuerkcanOppenheimer$36.00$37.90-5.01%-16.24%
Oct 21, 2025Morgan Stanley$44.00$35.0325.61%2.37%
Oct 21, 2025Leerink Partners$48.00$34.5438.97%11.68%
Oct 21, 2025Derek ArchilaWells Fargo$30.00$34.54-13.14%-30.20%
Sep 17, 2025Morgan Stanley$50.00$40.4423.64%16.33%
Sep 17, 2025Goldman Sachs$47.00$40.4416.22%9.35%
Sep 16, 2025Barclays$40.00$39.142.20%-6.93%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Nov 05, 2025H.C. WainwrightBuyBuyhold
Nov 05, 2025Cowen & Co.BuyBuyhold
Nov 05, 2025OppenheimerPerformPerformhold
Oct 21, 2025CitigroupMarket OutperformMarket Outperformhold
Sep 17, 2025Morgan StanleyOverweightOverweighthold
Aug 12, 2025H.C. WainwrightBuyBuyhold
Jul 11, 2025UBSNeutralNeutralhold
Jun 24, 2025JefferiesBuyBuyhold
Jun 24, 2025StephensEqual-WeightOverweightupgrade
Jun 23, 2025BenchmarkNeutralNeutralhold

Financial Forecast

EPS Forecast

$0 $1 $2 $3 $4 $5 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$0.36$0.73$0.57$0.65$1.80----
Avg Forecast$0.32$0.48$0.56$0.62$1.73$1.91$2.31$2.95$3.70
High Forecast$0.34$0.51$0.61$0.67$1.87$2.23$3.03$4.31$4.14
Low Forecast$0.30$0.45$0.53$0.49$1.55$1.57$1.20$1.26$3.49
Surprise %12.50%52.08%1.79%4.84%4.05%----

Revenue Forecast

$500M $1B $2B $2B $3B $4B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$987.54M$1.43B$1.61B$1.83B$2.17B----
Avg Forecast$988.00M$1.34B$1.60B$1.83B$2.16B$2.23B$2.47B$2.76B$3.10B
High Forecast$1.04B$1.40B$1.71B$1.87B$2.17B$2.46B$2.48B$2.77B$3.38B
Low Forecast$944.85M$1.28B$1.52B$1.82B$2.15B$2.15B$2.46B$2.74B$2.96B
Surprise %-0.05%7.20%0.48%-0.08%0.19%----

Net Income Forecast

$-500M $-100M $300M $700M $1B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$111.78M$231.06M$182.28M$207.76M$521.27M----
Avg Forecast$-224.71M$584.15M$677.63M$207.76M$549.48M$552.48M$682.27M$877.02M$1.19B
High Forecast$-131.24M$700.98M$813.16M$249.32M$600.20M$716.83M$974.37M$1.38B$1.33B
Low Forecast$-318.18M$467.32M$542.11M$166.21M$498.76M$504.33M$387.25M$406.53M$1.12B
Surprise %-149.74%-60.44%-73.10%--5.13%----

EXEL Forecast FAQ

Is Exelixis stock a buy?

Exelixis stock has a consensus rating of Buy, based on 32 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 17 Buy, 15 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Exelixis is a favorable investment for most analysts.

What is Exelixis's price target?

Exelixis's price target, set by 32 Wall Street analysts, averages $43.92 over the next 12 months. The price target range spans from $30 at the low end to $56 at the high end, suggesting a potential 2.19% change from the previous closing price of $42.98.

How does Exelixis stock forecast compare to its benchmarks?

Exelixis's stock forecast shows a 2.19% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Exelixis over the past three months?

  • November 2025: 15.00% Strong Buy, 45.00% Buy, 40.00% Hold, 0% Sell, 0% Strong Sell.
  • October 2025: 15.00% Strong Buy, 40.00% Buy, 45.00% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 15.00% Strong Buy, 40.00% Buy, 45.00% Hold, 0% Sell, 0% Strong Sell.

What is Exelixis’s EPS forecast?

Exelixis's average annual EPS forecast for its fiscal year ending in December 2025 is $1.91, marking a 6.11% increase from the reported $1.8 in 2024. Estimates for the following years are $2.31 in 2026, $2.95 in 2027, and $3.7 in 2028.

What is Exelixis’s revenue forecast?

Exelixis's average annual revenue forecast for its fiscal year ending in December 2025 is $2.23B, reflecting a 3.00% increase from the reported $2.17B in 2024. The forecast for 2026 is $2.47B, followed by $2.76B for 2027, and $3.1B for 2028.

What is Exelixis’s net income forecast?

Exelixis's net income forecast for the fiscal year ending in December 2025 stands at $552.48M, representing an 5.99% increase from the reported $521.27M in 2024. Projections indicate $682.27M in 2026, $877.02M in 2027, and $1.19B in 2028.